TransMedics Group Inc. shares decline by 9.5% on July 11.

TransMedics Group Inc (TMDX) shares fell 9.5% to $112.92 on July 11, down 36.34% from its 52-week high and 105.31% above its 52-week low. Analysts forecast an average target price of $145.75, with an upside of 29.07%. The consensus recommendation is 2.0, indicating "Outperform" status, and the estimated GF Value is $256.21, suggesting a 126.9% upside.

TransMedics Group Inc. (TMDX) experienced a significant drop in its share price on July 11, 2025, falling by 9.5% to $112.92. This decline represents a 36.34% decrease from its 52-week high and a 105.31% increase from its 52-week low. Analysts forecast an average target price of $145.75, with an upside potential of 29.07%. The consensus recommendation is 2.0, indicating an "Outperform" status, and the estimated GF Value is $256.21, suggesting a 126.9% upside.

The stock's performance on July 11, 2025, was notable for its volatility, with a 12.59% fluctuation between a day low of $109.59 and a day high of $123.39. This movement was accompanied by a 2 million share increase in volume, indicating heightened market interest. The stock has shown a downward trend over the last six out of ten trading days, with a cumulative decline of -13.53% during this period.

Analysts have provided varied ratings for TMDX, with Piper Sandler reaffirming an "overweight" rating and a target price of $145.00, Needham & Company LLC maintaining a "hold" rating, and Oppenheimer boosting its target price to $150.00 with an "outperform" rating. The consensus rating is "Moderate Buy" with an average price target of $127.33 [1].

Institutional investors have also shown interest in TMDX, with several large investors increasing their holdings. Jones Financial Companies Lllp boosted its holdings by 1,802.8% in the fourth quarter, Charles Schwab Investment Management Inc. by 9.5%, and Victory Capital Management Inc. by 76.3%. Arizona State Retirement System increased its holdings by 1.9%, and Raymond James Financial Inc. initiated a new position worth $3,845,000 [2].

Insider activity has been notable, with Director Edward M. Basile selling 6,000 shares and Director David Weill selling 732 shares, representing a significant decrease in their ownership stakes. Over the last quarter, insiders have sold 12,418 shares worth $1,512,613, owning 7.00% of the company's stock [1].

Technical analysis indicates few positive signals, with both short and long-term moving averages providing sell signals. The stock is expected to rise 46.01% over the next three months, with a 90% probability of holding a price between $164.20 and $232.00. Support levels are found at $111.50, and the recommended stop-loss is not set due to the negative evaluation of the stock [2].

For the upcoming trading day on Monday, July 14, 2025, analysts expect TMDX to open at $115.15 and move between $109.55 and $123.39 during the day.

References:
[1] https://www.marketbeat.com/instant-alerts/transmedics-group-nasdaqtmdx-stock-price-down-52-whats-next-2025-07-11/
[2] https://stockinvest.us/stock/TMDX